Relevance of additives and adjuvants in vaccines for allergic and toxic side effects;Hilfs- und zusatzstoffe von impfstoffen - Medizinische relevanz

Wiener Klinische Wochenschrift

Volumn 117, Issue 15-16, 2005, Pages 510-519

  Wiedermann Schmidt, Ursula ^a   Maurer, Wolfgang ^b  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

^b UNIV KLIN KINDER JUGENDHEILKUNDE   (Austria)

Author keywords

Additives; Antibiotics; DTH; Ovalbumin; Thiomersal; Toxicity; Type I hypersensitivity; Vaccination side effects

Indexed keywords

ADJUVANT; CEPHALOSPORIN; DRUG ADDITIVE; PENICILLIN G; THIOMERSAL; VACCINE; YELLOW FEVER VACCINE;

ALLERGIC REACTION; DEVELOPMENTAL DISORDER; DRUG EXPOSURE; HUMAN; REVIEW; VACCINATION;

EID: 25144498686     PISSN: 00435325     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00508-005-0405-0     Document Type: Review

References (32)

1. Abbas A, Lichtman AH, Pober J (2000) Diseases caused by Immune responses: hypersensitivity and autoimmunity. In: Cellular and molecular immunology, 4th edn. Saunders, Philadelphia, pp 404-415
2. Johansson SG, Hourihane JO, Bousquet J, Bruijnzeel-Koomen C, Dreborg S, Haahtela T, Kowalski ML, Mygind N, Ring J, van Cauwenberge P, van Hage-Hamsten M, Wuthrich B; EAACI (the European Academy of Allergology and Cinical Immunology) nomenclature task force. (2001) A revised nomenclature for allergy. An EAACI position statement from the EAACI nomenclature task force. Allergy 56: 813-814
3. Ambrosch F, Wiedermann G, Muller H (1984) A new ELISA micromethod for the determination of tetanus antibodies. Eine neue Mikromethode zur Bestimmung von Tetanusantikörpern. Zbl Bakt Hyg A 258: 173-182
4. Relyveld EH, Bizzini B, Gupta RK (1998) Rational approaches to reduce adverse reactions in man to vaccines containing tetanus and diphtheria toxoids. Vaccine 16: 1016-1023
5. James JM, Burks AW, Roberson PK, Sampson HA (1995) Safe administration of measles vaccine to children allergic to eggs. N Engl J Med 332: 1262-1266
6. Wiedermann G, Schemer O, Ambrosch F, Kraft D, Kollaritsch H, Kremsner P, Hauser P, Simoen E, Andre FE, Safary A (1988) Lack of induction of IgE and IgG antibodies to yeast in humans immunized with recombinant hepatitis B vaccines. Int Arch Allergy Applied Immunol 85: 130-132
7. Jilg W, Lorbeer B, Schmidt M, Wilske D, Zoulek G, Deinhardt F (1984) Clinical evaluation of a recombinant hepatitis B vaccine. Lancet ii: 1174-1175
8. Boy vat A, Akyol A, Gurgey E (2005) Contact sensitivity to preservatives in Turkey. Contact Dermatitis 52: 329-332
9. Vaccines for human use. European Pharmocopoeia, 3rd edn [Suppl 1999]: p 945
10. Tick-borne encephalitis vaccine (inactivated). European Pharmocopoeia, 3rd edn [Suppl 1999]: p 912
11. www.bgvv.de/cm/208/formaldehyd_in_shiitake_pilzen. pdf (aufgerufen 13.6.2005)
12. Sullivan JB Jr, Krieger GR (eds) (1992) Hazardous materials toxicology-clinical principles of environmental health. Williams and Wilkins, Baltimore
13. Schafer T, Bohler E, Ruhdorfer S, Weigl L, Wessner D, Filipiak B, Wichmann HE, Ring J (2001) Epidemiology of contact allergy in adults. Allergy 56: 1192-1196
14. Aberer W (1991) Vaccination despite thimerosal sensitivity. Contact Dermatitis 24: 6-10
15. Audicana MT, Munoz D, del Pozo MD, Fernandez E, Gastaminza G, Fernandez de Corres L (2002) Allergic contact dermatitis from mercury antiseptics and derivatives: study protocol of tolerance to intramuscular injections of thiomersal. Am J Contact Dermat 13: 3-9
16. Lowe I, Southern J (1994) The antimicrobial activity of phenoxyethanol in vaccines. Lett Appl Microbiol 18: 115-116
17. Chen CC, Chang MH, Lee HC, Twu Sj, Safary A (1999) Immunogenicity and reactogenicity of two recombinant hepatitis B vaccines in healthy adolescents on two-dose schedule. Acta Paediatr Taiwan 40: 157-160
18. Prieto L, Badiola C, Cortijo J, Perez-Frances C, Gutierrez V, Lanuza A (2005) Phenol-containing saline solution as a dilutant for adenosine 5′-monophosphate in bronchial challenge testing. Chest 127: 125-130
19. Wiedermann G (2000) Tollwut. In: Kollaritsch H, Wiedermann G (Hrsg) Leitfaden für Schutzimpfungen. Springer, Wien New York, S 247-255
20. Marth E, Kleinhappl B (2002) Albumin is a necessary stabilizer of TBE-vaccine to avoid fever in children after vaccination. Vaccine 20: 532-537
21. Sakaguchi M, Ogura H, Inouye S (1995) IgE antibodiy to gelatine in children with immediate type reactions to measles and mumps vaccines. J Allergy Clin Immunol 96: 563-565
22. Sakaguchi M, Yoshida M, Kuroda W, Harayama O, Matsunaga Y, Inouye S (1997) Systemic immediate type reactions to gelatine included in Japanese encephalitis vaccine. Vaccine 15: 121-122
23. Bergfors E, Trollfors B, Innerot A (2003) Unexpectedly high incidence of persistent itching nodules and delayed hypersensitivity to aluminium in children after the use of adsorbed vaccines from a single manufacturer. Vaccine 22: 64-69
24. Gherardi RK, Coquet M, Cherin P, Belec L, Moretto P, Dreyfus PA, Pellisier JF (2001) Macrophagic myofasciitis lesions assess long-term persistence of vaccine-derived aluminium hydroxide in muscle. Brain 124: 1821-1831
25. Verdier F, Burnett R, Michelet-Habchi C, Moretto P, Fievet-Groyne F, Sauzeat E (2005) Aluminium assay and evaluation of the local reaction at several time points after intramuscular administration of aluminium containing vaccines in the Cynomolgus monkey. Vaccine 23: 1359-1367
26. Myers GI, Davidson PW, Cox C, Shamlaye C, Cernichiari E, Clarkson TW (2000) Twentyseven years studying the human neurotoxicitiy of methyl-mercury exposure. Environ Res 83: 275-285
27. Pichichero ME, Cernichiari E, Lopreiato J, Treanot J (2002) Mercury concentrations and metabolism in infants receiving vaccines containing thimerosal: a descriptive study. Lancet 360: 1737-1741
28. EMEA Public Statement on Thiomersal containing Medicinal Products (1999) July EMEA/20962/99
29. WHO (2000) Thiomersal as a vaccine preservative. Wkly Epidemiol Rec 75: 12-16
30. Andrews N, Miller E, Grant E, Stowe J, Osborne V, Taylor B (2004) Thiomersal exposure in infants and developmental disorders: a retrospective cohort study in the United Kingdom does not support a causal association. Pediatrics 114: 584-591
31. Heron J, Golding J; ALSPAC Study Team (2004) Thimerosal exposure in infants and developmental disorders: a prospective cohort study in the United Kingdom does not support a causal association. Pediatrics 114: 577-583
32. Parker SK, Schwartz B, Todd J, Pickering LK (2004) Thiomersal containing vaccines and autistic spectrum disorder: a critical review of published original data. Pediatrics 114: 793-804